AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 61(6), 1999, pp. 973-977
Copyright © 1999 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilairatana, P
Right arrow Articles by Looareesuwan, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilairatana, P
Right arrow Articles by Looareesuwan, S
Related Collections
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 61, Issue 6, 973-977
Copyright © 1999 by American Society of Tropical Medicine and Hygiene

Research Articles


Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand

P Wilairatana, U Silachamroon, S Krudsood, P Singhasivanon, S Treeprasertsuk, V Bussaratid, W Phumratanaprapin, S Srivilirit, and S Looareesuwan

To define the current efficacy of Fansidar (F. Hoffmann-La Roche Ltd., Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study. Patients (15-65 years old) were assigned to 1 of 4 treatments regimens in a serial order. Ninety percent of the patients were infected at Thailand-Myanmar border. Patients in group I (n = 23) received Fansidar (3 tablets, 75 mg of pyrimethamine and 1,500 mg of sulfadoxine, a single dose on the first day), group II (n = 23) received Fansidar (3 tablets, 75 mg of pyrimethamine and 1,500 mg of sulfadoxine, a single dose on the first day) and then received primaquine (30 mg a day for 14 days), group III (n = 23) received primaquine (30 mg a day for 14 days), and group IV (n = 23) received artesunate (200 mg once a day for 3 days) and then primaquine (30 mg a day for 14 days). Cure rates on day 28 of follow-up were 40%, 100%, 100%, and 100% in groups I, II, II, and IV, respectively. There were 4 and 5 patients in group I showing post-treatment reappearance of parasitemia at < or = 16 days and between 17 and 28 days, respectively. Patients in the other 3 groups showed negative parasitemias within 7 days after treatment. Artesunate plus primaquine (group IV) cleared parasitemia faster than the other 3 regimens. There is a high proportion of ineffectiveness of Fansidar for treatment of P. vivax malaria and it should be no longer used for treatment of P. vivax malaria acquired at the Thailand-Myanmar border. A high dose of primaquine is safe and effective in the treatment of P. vivax malaria during the 28-day follow-up period.


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
J. K. Baird
Resistance to Therapies for Infection by Plasmodium vivax
Clin. Microbiol. Rev., July 1, 2009; 22(3): 508 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
J. Carmona-Fonseca, G. Alvarez, and A. Maestre
Methemoglobinemia and Adverse Events in Plasmodium vivax Malaria Patients Associated with High Doses of Primaquine Treatment
Am J Trop Med Hyg, February 1, 2009; 80(2): 188 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
S. Krudsood, N. Tangpukdee, P. Wilairatana, N. Phophak, J. K. Baird, G. M. Brittenham, and S. Looareesuwan
High-dose Primaquine Regimens against Relapse of Plasmodium vivax Malaria
Am J Trop Med Hyg, May 1, 2008; 78(5): 736 - 740.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. Leslie, M. I. Mayan, M. A. Hasan, M. H. Safi, E. Klinkenberg, C. J. M. Whitty, and M. Rowland
Sulfadoxine-Pyrimethamine, Chlorproguanil-Dapsone, or Chloroquine for the Treatment of Plasmodium vivax Malaria in Afghanistan and Pakistan: A Randomized Controlled Trial
JAMA, May 23, 2007; 297(20): 2201 - 2209.
[Abstract] [Full Text] [PDF]

Home page
 Mol Biol EvolHome page
A. M. Gunasekera, T. Wickramarachchi, D. E. Neafsey, I. Ganguli, L. Perera, P. H. Premaratne, D. Hartl, S. M. Handunnetti, P. V. Udagama-Randeniya, and D. F. Wirth
Genetic Diversity and Selection at the Plasmodium vivax Apical Membrane Antigen-1 (PvAMA-1) Locus in a Sri Lankan Population
Mol. Biol. Evol., April 1, 2007; 24(4): 939 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
G. ZHOU, J. SIRICHAISINTHOP, J. SATTABONGKOT, J. JONES, O. N. BJORNSTAD, G. YAN, and L. CUI
SPATIO-TEMPORAL DISTRIBUTION OF PLASMODIUM FALCIPARUM AND P. VIVAX MALARIA IN THAILAND
Am J Trop Med Hyg, March 1, 2005; 72(3): 256 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Hastings, J. D. Maguire, M. J. Bangs, P. A. Zimmerman, J. C. Reeder, J. K. Baird, and C. H. Sibley
Novel Plasmodium vivax dhfr Alleles from the Indonesian Archipelago and Papua New Guinea: Association with Pyrimethamine Resistance Determined by a Saccharomyces cerevisiae Expression System
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 733 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Tjitra, J. Baker, S. Suprianto, Q. Cheng, and N. M. Anstey
Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations
Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3947 - 3953.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society of Tropical Medicine and Hygiene.